A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID)
NCT ID: NCT05541380
Last Updated: 2025-04-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Total Enrollment
300 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-08-29
Study Completion Date
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Because one cancer type may harbor various genetic aberrations, it is not enough to check only one or a few genes for a patient to choose the adequate treatment. Because the advance in multiplex genomic testing, several NGS-based cancer-associated genetic panel tests (oncopanel) have been developed and used to identify the genetic alterations, particularly the actionable genes, in each patient. Large scale checks of oncopanel have been executed in US. The study showed the genetic alterations in various cancer types and 11% of the patients had further molecular targeted therapy based on the result of the oncopanel test. Similar program was also conducted in Japan. Moreover, the oncopanel tests have been implicated in their clinical practice and the cost was reimbursed by the government of Japan and Korea recently. Precision medicine and such personalized treatment is the trend of cancer treatment. The trend of such treatment patterns is also observed in Taiwan. The genetic background for cancer treatment may also be different among different areas and races. There is short of genetic alteration data in Taiwanese cancer patients. To understand the landscape of genetic aberrations of cancer in Taiwan, large scale survey of the cancer patients is indicated. investigators propose to evaluate the landscape of genetic aberrations in cancer patients via oncopaenl test and collect the clinical data of the patients. The result of the oncopanel test will be provided to patients and their attending physicians as reference for their further treatment. In addition, investigators want to correlate the clinical outcome with the genetic aberrations of the cancer patients in Taiwan. Thyroid cancers are divided into differentiated thyroid cancer (DTC), medullary and anaplastic carcinoma. The majority of the patients are DTC. Different from other cancer type, radioactive iodine (RAI) therapy is usually the main treatment for advanced DTC. Multitargeted kinase inhibitors are indicated for advanced DTC refractory to RAI therapy and advanced medullary thyroid cancer. For anaplastic thyroid cancer, the prognosis is poor in spite of chemotherapy or radiation therapy. BRAF or NTRK targeted therapies are suggested if the patients have these genetic aberrations. Thyroid cancer patients have various genetic aberrations, including BRAF, RAS, RET, NTRK and others. Various gene specific kinase inhibitors have been developed and demonstrated the efficacy for the treatment of advanced thyroid cancer in addition to current standard therapies. Thyroid cancer is a cancer type with high percentage of driver gene aberration, however the genetic landscape of thyroid cancer is not well understood in Taiwan. In the current study, investigators want to investigate the genetic aberrations of advanced thyroid cancers by performing the NGS oncopanel.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas
NCT06863805
Thyroid Carcinoma
RECRUITING
Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer
NCT05463107
Thyroid Cancer
Follicular Thyroid Cancer
RECRUITING
Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer
NCT01109420
Non-Medullary Thyroid Cancer
RECRUITING
IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
NCT05014698
Differentiated Thyroid Cancer
Thyroid Cancer, Nonmedullary
TERMINATED
NA
The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan
NCT05522881
Oropharyngeal Squamous Cell Carcinoma
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cancer is the most common cause of death in Taiwan since 1982. The incidence of cancer is increasing worldwide, including Taiwan. Cancers in early stage can usually be treated by surgery with a good prognosis. However, the prognosis for recurrent, locally advanced or metastatic cancers is poor with a shorter survival. Systemic treatments are usually indicated for these patients. Chemotherapy is the mainstay for advanced cancer patients. However, the advances in the understanding of cancer biology and identification of targeted therapeutics not only increase the treatment strategies of cancer but also improve the survival and quality of life of the cancer patients. There are more and more molecularly targeted therapy developed and approved for the treatment of advanced cancer patients currently, which makes the beginning of precision cancer medicine. There are more and more treatments can be used based on the genetic aberrations of the cancers. Because one cancer type may harbor various genetic aberrations, it is not enough to check only one or a few genes for a patient to choose the adequate treatment. Because the advance in multiplex genomic testing, several NGS-based cancer-associated genetic panel tests (oncopanel) have been developed and used to identify the genetic alterations, particularly the actionable genes, in each patient. Large scale checks of oncopanel have been executed in US. The study showed the genetic alterations in various cancer types and 11% of the patients had further molecular targeted therapy based on the result of the oncopanel test. Similar program was also conducted in Japan. Moreover, the oncopanel tests have been implicated in their clinical practice and the cost was reimbursed by the government of Japan and Korea recently. Precision medicine and such personalized treatment is the trend of cancer treatment. The trend of such treatment patterns is also observed in Taiwan. The genetic background for cancer treatment may also be different among different areas and races. There is short of genetic alteration data in Taiwanese cancer patients. To understand the landscape of genetic aberrations of cancer in Taiwan, large scale survey of the cancer patients is indicated. investigators propose to evaluate the landscape of genetic aberrations in cancer patients via oncopaenl test and collect the clinical data of the patients. The result of the oncopanel test will be provided to patients and their attending physicians as reference for their further treatment. In addition, investigators want to correlate the clinical outcome with the genetic aberrations of the cancer patients in Taiwan. Thyroid cancers are divided into differentiated thyroid cancer (DTC), medullary and anaplastic carcinoma. The majority of the patients are DTC. Different from other cancer type, radioactive iodine (RAI) therapy is usually the main treatment for advanced DTC. Multitargeted kinase inhibitors are indicated for advanced DTC refractory to RAI therapy and advanced medullary thyroid cancer. For anaplastic thyroid cancer, the prognosis is poor in spite of chemotherapy or radiation therapy. BRAF or NTRK targeted therapies are suggested if the patients have these genetic aberrations. Thyroid cancer patients have various genetic aberrations, including BRAF, RAS, RET, NTRK and others. Various gene specific kinase inhibitors have been developed and demonstrated the efficacy for the treatment of advanced thyroid cancer in addition to current standard therapies. Thyroid cancer is a cancer type with high percentage of driver gene aberration, however the genetic landscape of thyroid cancer is not well understood in Taiwan. In the current study, investigators want to investigate the genetic aberrations of advanced thyroid cancers by performing the NGS oncopanel. Then investigators can understand the genetic aberrations of these patients in Taiwan and help search potential treatment targets for these patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Thyroid Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A
patients who were pathologically (histologically) diagnosed as papillary carcinoma (PTC). They are in advanced stage and need systemic therapies. These patients may be unresectable, recurrent, persistent, or metastatic disease with RAI refractory or ineligible and need systemic therapies.
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Intervention Type
OTHER
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Cohort B
patients who were pathologically diagnosed as DTC other than PTC, which includes follicular carcinoma, Hurthle cell carcinoma, and poorly differentiated carcinoma. The patients are in advanced stage and need systemic therapies. These patients may be unresectable, recurrent, persistent, or metastatic disease with RAI refractory or ineligible and need systemic therapies.
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Intervention Type
OTHER
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Cohort C
patients who were pathologically diagnosed as medullary thyroid cancer (MTC) with persistent disease.
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Intervention Type
OTHER
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Cohort D
patients who were pathologically diagnosed as anaplastic thyroid cancer (ATC).
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Intervention Type
OTHER
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Cohort E
the patients who had performed large scale NGS oncopanel test previously and fulfil with the criteria in cohort A, B, C, or D.
The patients must meet all the inclusion criteria and none of the exclusion criteria in each cohort.
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Intervention Type
OTHER
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Cohort A:
1. Pathologically confirmed papillary thyroid carcinoma (PTC).
2. The patient is in advanced stage, which includes recurrent, metastatic, unresectable, or persistent disease.
3. The patients are RAI-refractory\* or ineligible for RAI therapy\*\*.
\*The definitions of RAI-refractory are one of the following criteria: no uptake of RAI in the tumor, uptake of RAI in some tumors but no uptake in other tumors, disease progression in spite of RAI uptake in the tumors, or accumulated RAI dose ≥ 600 mCi.
\*\*the definitions of ineligible for RAI therapy are one of the following criteria: patients are unable to have RAI therapy due to some reasons, such as not received total thyroidectomy, unable to receive total thyroidectomy, or unable to have self-care in the isolation room.
4. The patient needs systemic therapy.
5. There are archived tumor samples available and the date of archived tumor sampling must be not more than 5 years from screening date. If there is no archived tumor sample available or the tumor sampling date is more than 5 years from screening date, re-biopsy is needed. If the quality of tumor sample is not fit for NGS oncopanel test, re-biopsy is needed.
6. Age ≥ the legal age.
7. Life expectancy greater than 6 months.
8. Capable of understanding and complying with the protocol requirements and signed informed consent.
Cohort B:
1. Pathologically confirmed differentiated thyroid cancer (DTC) other than PTC, which includes follicular thyroid cancer (FTC), Hurthle cell carcinoma, and poorly-differentiated thyroid cancer.
2. The patient is in advanced stage, which includes recurrent, metastatic, unresectable, or persistent disease.
3. The patients are RAI-refractory\* or ineligible for RAI therapy\*\*.
\*The definitions of RAI-refractory are one of the following criteria: no uptake of RAI in the tumor, uptake of RAI in some tumors but no uptake in other tumors, disease progression in spite of RAI uptake in the tumors, or accumulated RAI dose ≥ 600 mCi.
\*\*the definitions of ineligible for RAI therapy are one of the following criteria: patients are unable to have RAI therapy due to some reasons, such as not received total thyroidectomy, unable to receive total thyroidectomy, or unable to have self-care in the isolation room.
4. The patient needs systemic therapy.
5. There are archived tumor samples available and the date of archived tumor sampling must be not more than 5 years from screening date. If there is no archived tumor sample available or the tumor sampling date is more than 5 years from screening date, re-biopsy is needed. If the quality of tumor sample is not fit for NGS oncopanel test, re-biopsy is needed.
6. Age ≥ the legal age.
7. Life expectancy greater than 6 months.
8. Capable of understanding and complying with the protocol requirements and signed informed consent.
Cohort C:
1. Pathologically confirmed medullary thyroid carcinoma (MTC).
2. The patient is in advanced stage, which includes recurrent, metastatic, unresectable, or persistent disease.
3. There are archived tumor samples available and the date of archived tumor sampling must be not more than 5 years from screening date. If there is no archived tumor sample available or the tumor sampling date is more than 5 years from screening date, re-biopsy is needed. If the quality of tumor sample is not fit for NGS oncopanel test, re-biopsy is needed.
4. Age ≥ the legal age.
5. Life expectancy greater than 6 months.
6. Capable of understanding and complying with the protocol requirements and signed informed consent.
Cohort D:
1. Pathologically confirmed anaplastic thyroid carcinoma (ATC).
2. There are archived tumor samples available and the date of archived tumor sampling must be not more than 5 years from screening date. If there is no archived tumor sample available or the tumor sampling date is more than 5 years from screening date, re-biopsy is needed. If the quality of tumor sample is not fit for NGS oncopanel test, re-biopsy is needed.
3. Age ≥ the legal age.
4. Capable of understanding and complying with the protocol requirements and signed informed consent.
Cohort E:
\-
1. Pathologically confirmed papillary thyroid carcinoma (PTC).
2. The patient is in advanced stage, which includes recurrent, metastatic, unresectable, or persistent disease.
3. The patients are RAI-refractory\* or ineligible for RAI therapy\*\*.
\*The definitions of RAI-refractory are one of the following criteria: no uptake of RAI in the tumor, uptake of RAI in some tumors but no uptake in other tumors, disease progression in spite of RAI uptake in the tumors, or accumulated RAI dose ≥ 600 mCi.
\*\*the definitions of ineligible for RAI therapy are one of the following criteria: patients are unable to have RAI therapy due to some reasons, such as not received total thyroidectomy, unable to receive total thyroidectomy, or unable to have self-care in the isolation room.
4. The patient needs systemic therapy.
5. There are archived tumor samples available and the date of archived tumor sampling must be not more than 5 years from screening date. If there is no archived tumor sample available or the tumor sampling date is more than 5 years from screening date, re-biopsy is needed. If the quality of tumor sample is not fit for NGS oncopanel test, re-biopsy is needed.
6. Age ≥ the legal age.
7. Life expectancy greater than 6 months.
8. Capable of understanding and complying with the protocol requirements and signed informed consent.
Cohort B:
1. Pathologically confirmed differentiated thyroid cancer (DTC) other than PTC, which includes follicular thyroid cancer (FTC), Hurthle cell carcinoma, and poorly-differentiated thyroid cancer.
2. The patient is in advanced stage, which includes recurrent, metastatic, unresectable, or persistent disease.
3. The patients are RAI-refractory\* or ineligible for RAI therapy\*\*.
\*The definitions of RAI-refractory are one of the following criteria: no uptake of RAI in the tumor, uptake of RAI in some tumors but no uptake in other tumors, disease progression in spite of RAI uptake in the tumors, or accumulated RAI dose ≥ 600 mCi.
\*\*the definitions of ineligible for RAI therapy are one of the following criteria: patients are unable to have RAI therapy due to some reasons, such as not received total thyroidectomy, unable to receive total thyroidectomy, or unable to have self-care in the isolation room.
4. The patient needs systemic therapy.
5. There are archived tumor samples available and the date of archived tumor sampling must be not more than 5 years from screening date. If there is no archived tumor sample available or the tumor sampling date is more than 5 years from screening date, re-biopsy is needed. If the quality of tumor sample is not fit for NGS oncopanel test, re-biopsy is needed.
6. Age ≥ the legal age.
7. Life expectancy greater than 6 months.
8. Capable of understanding and complying with the protocol requirements and signed informed consent.
Cohort C:
1. Pathologically confirmed medullary thyroid carcinoma (MTC).
2. The patient is in advanced stage, which includes recurrent, metastatic, unresectable, or persistent disease.
3. There are archived tumor samples available and the date of archived tumor sampling must be not more than 5 years from screening date. If there is no archived tumor sample available or the tumor sampling date is more than 5 years from screening date, re-biopsy is needed. If the quality of tumor sample is not fit for NGS oncopanel test, re-biopsy is needed.
4. Age ≥ the legal age.
5. Life expectancy greater than 6 months.
6. Capable of understanding and complying with the protocol requirements and signed informed consent.
Cohort D:
1. Pathologically confirmed anaplastic thyroid carcinoma (ATC).
2. There are archived tumor samples available and the date of archived tumor sampling must be not more than 5 years from screening date. If there is no archived tumor sample available or the tumor sampling date is more than 5 years from screening date, re-biopsy is needed. If the quality of tumor sample is not fit for NGS oncopanel test, re-biopsy is needed.
3. Age ≥ the legal age.
4. Capable of understanding and complying with the protocol requirements and signed informed consent.
Cohort E:
\-
Exclusion Criteria
Cohort A:
1. Inability and unwillingness to give informed consent.
2. The patients have no evidence of disease before systemic treatment.
3. The patients have stable residual disease or metastatic disease without progression and do not need systemic therapies.
4. The patients do not intend to have systemic therapies.
5. Patients do not agree to provide archived tumor samples and blood samples or they do not agree to do tumor biopsy when archived tumor samples are not available or inadequate for NGS oncopanel test.
6. The date of archived tumor sampling is more than 5 years from screening date.
7. Patients refuse for collection of clinical data and follow-up.
8. Mental status is not fit for further treatment or data collection.
Cohort B:
1. Inability and unwillingness to give informed consent.
2. The patients have no evidence of disease before systemic treatment.
3. The patients have stable residual disease or metastatic disease without progression and do not need systemic therapies.
4. The patients do not intend to have systemic therapies.
5. Patients do not agree to provide archived tumor samples and blood samples or they do not agree to do tumor biopsy when archived tumor samples are not available or inadequate for NGS oncopanel test.
6. The date of archived tumor sampling is more than 5 years from screening date.
7. Patients refuse for collection of clinical data and follow-up.
8. Mental status is not fit for further treatment or data collection.
Cohort C:
1. Inability and unwillingness to give informed consent.
2. The patients have no evidence of disease before systemic treatment.
3. Patients do not agree to provide archived tumor samples and blood samples or they do not agree to do tumor biopsy when archived tumor samples are not available or inadequate for NGS oncopanel test.
4. The date of archived tumor sampling is more than 5 years from screening date.
5. Patients refuse for collection of clinical data and follow-p.
6. Mental status is not fit for further treatment or data collection.
Cohort D:
1. Inability and unwillingness to give informed consent.
2. Patients do not agree to provide archived tumor samples and blood samples or they do not agree to do tumor biopsy when archived tumor samples are not available or inadequate for NGS oncopanel test.
3. The date of archived tumor sampling is more than 5 years from screening date.
4. Patients refuse for collection of clinical data and follow up.
Cohort E:
\-
1. Inability and unwillingness to give informed consent.
2. The patients have no evidence of disease before systemic treatment.
3. The patients have stable residual disease or metastatic disease without progression and do not need systemic therapies.
4. The patients do not intend to have systemic therapies.
5. Patients do not agree to provide archived tumor samples and blood samples or they do not agree to do tumor biopsy when archived tumor samples are not available or inadequate for NGS oncopanel test.
6. The date of archived tumor sampling is more than 5 years from screening date.
7. Patients refuse for collection of clinical data and follow-up.
8. Mental status is not fit for further treatment or data collection.
Cohort B:
1. Inability and unwillingness to give informed consent.
2. The patients have no evidence of disease before systemic treatment.
3. The patients have stable residual disease or metastatic disease without progression and do not need systemic therapies.
4. The patients do not intend to have systemic therapies.
5. Patients do not agree to provide archived tumor samples and blood samples or they do not agree to do tumor biopsy when archived tumor samples are not available or inadequate for NGS oncopanel test.
6. The date of archived tumor sampling is more than 5 years from screening date.
7. Patients refuse for collection of clinical data and follow-up.
8. Mental status is not fit for further treatment or data collection.
Cohort C:
1. Inability and unwillingness to give informed consent.
2. The patients have no evidence of disease before systemic treatment.
3. Patients do not agree to provide archived tumor samples and blood samples or they do not agree to do tumor biopsy when archived tumor samples are not available or inadequate for NGS oncopanel test.
4. The date of archived tumor sampling is more than 5 years from screening date.
5. Patients refuse for collection of clinical data and follow-p.
6. Mental status is not fit for further treatment or data collection.
Cohort D:
1. Inability and unwillingness to give informed consent.
2. Patients do not agree to provide archived tumor samples and blood samples or they do not agree to do tumor biopsy when archived tumor samples are not available or inadequate for NGS oncopanel test.
3. The date of archived tumor sampling is more than 5 years from screening date.
4. Patients refuse for collection of clinical data and follow up.
Cohort E:
\-
Minimum Eligible Age
20 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Health Research Institutes, Taiwan
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
Site Status
Kaohsiung Veterans General Hospital
Kaohsiung City, , Taiwan
Site Status
China Medical University Hospital
Taichung, , Taiwan
Site Status
National Cheng Kung University Hospital
Tainan City, , Taiwan
Site Status
National Taiwan University Cancer Center
Taipei, , Taiwan
Site Status
National Taiwan University Hospital
Taipei, , Taiwan
Site Status
Taipei Veterans General Hospital
Taipei, , Taiwan
Site Status
Tri-service General Hospital
Taipei, , Taiwan
Site Status
Linkou Chang Gung Memorial Hospital
Taoyuan District, , Taiwan
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Taiwan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T2322
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Investigating Utility of ctDNA and Tumour Evolution in Advanced Thyroid Cancer
NCT05837260
RECRUITING
Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules
NCT02352766
COMPLETED
Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer
NCT03170804
UNKNOWN
Single Cell Sequencing Analysis of Thymoma
NCT04162691
UNKNOWN
Molecular Markers in Thyroid Cancer
NCT00598364
COMPLETED
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
NCT06550427
RECRUITING
Hereditary Risk Factors for Thyroid Cancer
NCT02747888
RECRUITING
NA
Diagnosing Thyroid Cancer Using a Blood Test
NCT01586520
COMPLETED
Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients
NCT04821895
ACTIVE_NOT_RECRUITING
ctDNA in Patients With Thyroid Nodules
NCT02778412
TERMINATED
Proteomics of Papillary Thyroid Carcinoma
NCT02814032
UNKNOWN
UGT1A1 Genotyping in Taiwanese Cancer Patients
NCT05792943
UNKNOWN
Pyrosequencing of the BRAFV600E Mutation
NCT00551486
COMPLETED
Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma : Microarray Analysis
NCT01384669
COMPLETED
A Gene Hunting Study for Familial Papillary Thyroid Cancer
NCT02776969
ACTIVE_NOT_RECRUITING
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
NCT01005654
RECRUITING
Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules
NCT03392402
COMPLETED
Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY
NCT05766098
RECRUITING
Molecular and Genomic Profiling of Head and Neck Tumors
NCT00200486
RECRUITING
The Registry Study of Genetic Alterations of Esophageal Cancer in Taiwan
NCT04996095
ACTIVE_NOT_RECRUITING
Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors
NCT01050413
UNKNOWN
Genomic Predictors of Papillary Microcarcinoma Disease Progression
NCT02363595
RECRUITING
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
RECRUITING
DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer
NCT00898664
COMPLETED